ANGO · Company research
AngioDynamics, Inc. (ANGO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist (NASDAQ:ANGO) - Seeking Alpha | AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist (NASDAQ:ANGO) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| AngioDynamics, Inc. (ANGO) Stock Price, News, Quote & History - Yahoo! Finance Canada | AngioDynamics, Inc. (ANGO) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| Humana applies Medicare coverage rules to a non-heat treatment for some prostate and liver cancer patients. - Stock Titan | Humana applies Medicare coverage rules to a non-heat treatment for some prostate and liver cancer patients. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| A Look at AngioDynamics Inc (ANGO) After 4.4% Decline -- GF Value $10.48 vs Price $10.90 - GuruFocus | A Look at AngioDynamics Inc (ANGO) After 4.4% Decline -- GF Value $10.48 vs Price $10.90 GuruFocus | View source ↗ | GuruFocus | Oct 13, 2026 | neutral | 0 | 0.6 |
| ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - TradingView | ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y TradingView | View source ↗ | TradingView | Oct 9, 2026 | neutral | 0 | 0.6 |
| ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y | AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y | AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - TradingView | ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y TradingView | View source ↗ | TradingView | Oct 9, 2026 | neutral | 0 | 0.6 |
| AngioDynamics (ANGO) Prepares for Earnings Amid Mixed Signals on Valuation and Insider Activity - GuruFocus | AngioDynamics (ANGO) Prepares for Earnings Amid Mixed Signals on Valuation and Insider Activity GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress - Simply Wall Street | AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| ANGIODYNAMICS INC ($ANGO) President, CEO 2026 Pay Revealed - Quiver Quantitative | ANGIODYNAMICS INC ($ANGO) President, CEO 2026 Pay Revealed Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 8, 2026 | neutral | 0 | 0.6 |
| ANGIODYNAMICS INC ($ANGO) President, CEO 2026 Pay Revealed - Quiver Quantitative | ANGIODYNAMICS INC ($ANGO) President, CEO 2026 Pay Revealed Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics (ANGO) Reports Q1 Revenue Growth Amid Ongoing Prof - GuruFocus | AngioDynamics (ANGO) Reports Q1 Revenue Growth Amid Ongoing Prof GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics Stock Is Falling Thursday: What's Going On? - Benzinga | AngioDynamics Stock Is Falling Thursday: What's Going On? Benzinga | View source ↗ | Benzinga | Oct 8, 2026 | neutral | 0 | 0.6 |
| Sales rose 6.9% at AngioDynamics (ANGO), but the quarter still ended in a loss. - Stock Titan | Sales rose 6.9% at AngioDynamics (ANGO), but the quarter still ended in a loss. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics stock slips 4% despite beating estimates on Med Tech growth - Yahoo Finance | AngioDynamics stock slips 4% despite beating estimates on Med Tech growth Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates | AngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance | AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates | AngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| After 10 years, AngioDynamics' CEO is retiring - Stock Titan | After 10 years, AngioDynamics' CEO is retiring Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| $ANGO stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $ANGO stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 6, 2026 | neutral | 0 | 0.6 |
| AngioDynamics, Inc. (ANGO) stock price, news, quote and history - Yahoo Finance UK | AngioDynamics, Inc. (ANGO) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 3, 2026 | neutral | 0 | 0.6 |
| AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance | AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Jul 14, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.